Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$5.39 - $7.29 $2.65 Million - $3.59 Million
492,000 New
492,000 $3.14 Million
Q3 2018

Nov 13, 2018

SELL
$20.86 - $33.33 $2.71 Million - $4.33 Million
-130,000 Closed
0 $0
Q2 2018

Aug 10, 2018

BUY
$25.0 - $27.75 $3.25 Million - $3.61 Million
130,000 New
130,000 $3.48 Million

Others Institutions Holding AUTL

About Autolus Therapeutics plc


  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $272M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Monashee Investment Management LLC Portfolio

Follow Monashee Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Monashee Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Monashee Investment Management LLC with notifications on news.